To date they have been distributed 26 million units of this treatment around the world in countries in Europe, the United States and Canada. In Mexico, negotiations are open to increase the dose if necessary, since it is difficult to estimate how much medication will be required.
“The company has been able to put all its production capacities back in record time and then the product is available,” adds Murillo, who has defended the price of the antiviral in forums and conferences.
The pharmaceutical company has maintained alliances with the government since the beginning of the pandemic. Of the 224.3 million vaccines that were supplied in the country until June 14, the 23% are from Pfizerdown from 49.5% of AstraZeneca doses, according to federal government data.
Earnings and medical research
So far, the Paxlovid vaccine and treatment have driven the company’s global sales to a record level during the second quarter of this year, in which it reported a turnover of $27.7 billionwhich represents a 47% rise in their annual comparison.
Pfizer’s Covid vaccine paid $8.8 billion to income, while sales of Paxlovid totaled in 8.1 billionaccording to the financial statement of the pharmaceutical company, which maintained its annual sales projection for the vaccine at $32 million and Paxlovid at $22 billion.
“The vaccine and this antiviral treatment have been very important for the company in 2021 and 2022, almost have represented 50% of our turnover and thus represents 100% growth for the company,” Murillo said. Pfizer invests approximately 15% of its turnover in research and development.
Without disclosing data, Carlos Murillo declared that Mexico is one of the countries in Latin America with the highest growth in 2020 and 2021 for the company, with an opportunity for investments in clinical research, given that progress has been made in various studies of future molecules made in Mexico. . 11% of the clinical studies that Pfizer carries out globally are carried out in the country.
“The challenge that the countries in Latin America have, and what we have to work on, are the regulatory frameworks and more efficient and faster processes that allow us to be more competitive with the rest of the world in order to attract more investment in the clinical area. Our countries should be able to capture a larger portion of that, we have the capabilities, we have the means, we have the populations that can benefit from this.”
Pfizer arrived in Mexico in 1951, marking 71 years in the country. In 1958 it opened its pharmaceutical plant in Toluca, in the State of Mexico, and 70% of its production is for local consumption and 30% is exported to Latin America.